Searched for
BIOCON UPDATES
JEE Advanced Result 2026 declared: Check direct link for registration, JoSAA Counselling, AAT Schedule dates and moreJEE Advanced Result 2026 out at jeeadv.ac.in: IIT Roorkee announced JEE Advanced 2026 results on May 31st. Qualified students can now regis...- 'Thank God' Kiran Mazumdar Shaw did not become a doctor: When Dr Devi Shetty shared a life lesson from Biocon founder's inspiring journeyA missed medical college admission propelled Kiran Mazumdar-Shaw towards a different path, ultimately leading to the founding of Biocon. Re...
- Biocon shares in focus after Q3 PAT drops 96% YoY, 1.5% additional stake acquisition in subsidiaryBiocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the...
- Biocon shares surge over 4% after Malaysia unit gets clearance from the USFDABiocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated. This followed a...
- Stock Radar: Biocon stock price breaks out from upper band of a Symmetrical Triangle; should you buy?Biocon Ltd has broken out of the Symmetrical Triangle formation on daily charts, suggesting a potential rise in stock price. Experts advise...
- Biocon shares zoom 4% as Jefferies upgrades to "hold" amid positive news inflow, sets Rs 400 targetBiocon share price: This upgrade reflects a more positive outlook on the company following recent favorable news flow, particularly concern...
- Stocks in news: DMart, ITC, Hero MotoCorp, Pricol, NHPCAvenue Supermarts, which operates retail chain DMart on Thursday reported a 17% year-on-year jump in its stanalone revenue for the quarter ...
- Biocon shares surge 5% after USFDA classifies Bengaluru site as VAIBiocon Share Price: Biocon shares surged 5.4% after FDA classified its Bengaluru facility as Voluntary Action Indicated (VAI). The stock is...
- Biocon acquires Eywa Pharma's US-based plant for $7.7 millionBiocon Limited announced that its wholly-owned subsidiary, Biocon Generics Inc., has acquired Eywa Pharma Inc.’s oral solid dosage manufact...
- Competition Commission of India clears Kotak-Biocon Biologics dealThe investment will help Biocon Biologics' acquisition of the biosimilars business of its partner Viatris.
- Biocon Q1 Results: Profit drops 30% YoY to Rs 101 crore, revenue jumps 59%The company attributed the drop in net profit to depreciation, amortisation and interest increase of Rs 353 crore over last year primarily ...
- Biocon Q4 Results: Cons PAT grows 31% YoY to Rs 313 crore, revenue surges 57%The board has recommended a final dividend payout of Rs 1.50 per share. In FY23, Biocon’s revenue grew almost 37% to Rs 11,174 crore, while...
- Biocon plunges 5% even as Q1 profit rises 71%Siddharth Mittal, CEO & Managing Director, Biocon, said, “The strong year-on-year growth of the segment was driven by both our API and Form...
- Biocon reports 64% jump in Q4 net riding on biologicsBiocon reported a 64 per cent jump in its net profit for the quarter ending March 2019.
- USFDA issues CRL for proposed biosimilar Pegfilgrastim: BioconThe company said it does not expect the CRL to impact the timing of the launch of biosimilar Pegfilgrastim in the US market.
- Biocon gets CRL from USFDA for anti-cancer drugThe company, however, said it does not expect this CRL to impact the commercial launch timing of biosimilar Pegfilgrastim in the US.
- US drugmaker Bristol Myers Squibb out of Biocon’s oral insulin projectBMS had taken a wider decision to sell its entire diabetes franchise to British drug maker AstraZeneca, while narrowing its own focus on de...
- Biocon targets emerging, developed markets with biosimilars"Biocon aims to provide high quality biosimilars to patients across the world, both in emerging and developed markets," Kiran Mazumdar-Shaw...
- Is it time to book profits on Biocon counter post Syngene listing?Biocon has gained nearly 9 per cent in the past six months, compared to a 2 per cent fall in the BSE benchmark Sensex.
- Biocon has substantial upsides: Rajesh Jain"Amongst the Indian tier 2 pharma companies, Biocon is certainly a pick."
Load More
